Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    TriSalus Life Sciences In...

    NASDAQ: TLSI · Real-Time Price · USD
    4.97
    -0.10 (-1.97%)
    At close: May 14, 2025, 3:59 PM
    4.90
    -1.41%
    After-hours: May 14, 2025, 04:05 PM EDT
    -1.97%
    Bid 4.7
    Market Cap 160.71M
    Revenue (ttm) 29.43M
    Net Income (ttm) -30.06M
    EPS (ttm) -1.31
    PE Ratio (ttm) -3.79
    Forward PE -15.15
    Analyst Buy
    Ask 5.56
    Volume 23,939
    Avg. Volume (20D) 49,906
    Open 5.13
    Previous Close 5.07
    Day's Range 4.91 - 5.25
    52-Week Range 3.50 - 10.17
    Beta 0.50

    About TLSI

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol TLSI
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for TLSI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    TriSalus Life Sciences Inc. is scheduled to release its earnings on May 15, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    6 months ago
    -10.89%
    TriSalus Life Sciences shares are trading lower af... Unlock content with Pro Subscription
    news image

    2 days ago · businesswire.com

    TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call

    DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by in...

    news image

    1 month ago · zacks.com

    TriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock?

    TriSalus Life Sciences, Inc. (TLSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further ...

    news image

    1 month ago · seekingalpha.com

    TriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still Risks

    TriSalus Life Sciences aims to achieve positive cash flow by 2025, driven by expanding sales of their TriNav system and reducing operating expenses. The PERIO-03 trial for nelitolimod, a potential tre...

    news image

    1 month ago · seekingalpha.com

    TriSalus Life Sciences, Inc. (TLSI) Q4 2024 Earnings Call Transcript

    TriSalus Life Sciences, Inc. (NASDAQ:TLSI ) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Jeremy Feffer - Managing Director, LifeSci Advisors Mary Szela - President &...

    news image

    1 month ago · zacks.com

    TriSalus Life Sciences, Inc. (TLSI) Reports Q4 Loss, Tops Revenue Estimates

    TriSalus Life Sciences, Inc. (TLSI) came out with a quarterly loss of $0.35 per share in line with the Zacks Consensus Estimate. This compares to loss of $1.56 per share a year ago.

    news image

    1 month ago · businesswire.com

    TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update

    DENVER--(BUSINESS WIRE)--TriSalus Life Sciences Inc., (Nasdaq: TLSI), oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating our innov...

    news image

    1 month ago · businesswire.com

    TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping

    DENVER--(BUSINESS WIRE)--TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our innovative deli...

    news image

    2 months ago · businesswire.com

    TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model”

    DENVER--(BUSINESS WIRE)--TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), TriSalus Life Sciences, which seeks to transform outcomes for patients with solid tumors by integra...

    Add to Watchlist